EichorEICHOR
Condition: High Risk Mds Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: High Risk Mds

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment o
Phase 1 · 2 location(s) · Catherine Bollard · NCT02203903Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myelo
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03214562A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Phase 1/Phase 2 · 8 location(s) · Chordia Therapeutics, Inc. · NCT05732103HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Phase 1 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT06594445Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantat
Phase 2 · 1 location(s) · Yehui Tan · NCT07047183Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT06802315A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Phase 1 · 11 location(s) · Crossbow Therapeutics, Inc. · NCT06994676Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05817955Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syn
Phase 3 · 2 location(s) · Ascentage Pharma Group Inc. · NCT06641414CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04493164Study of REM-422 in Patients With AML or Higher Risk MDS
Phase 1 · 9 location(s) · Remix Therapeutics · NCT06297941Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078The Patient Cohort of the National Center for Precision Medicine in Leukemia
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05326919A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Phase 2 · 15 location(s) · Akeso · NCT06196203Cord Blood Transplant in Adults With Blood Cancers
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT05884333211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplanta
Phase 2 · 5 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06918834Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
Phase N/A · 1 location(s) · University of Rochester · NCT01311258Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT04644016Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, M
Phase 1/Phase 2 · 1 location(s) · Uma Borate · NCT06523556Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06158828SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplas
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT03113643Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Phase 3 · 46 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04184505A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Phase 1/Phase 2 · 1 location(s) · Ciusss de L'Est de l'Île de Montréal · NCT07301866VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Phase 1/Phase 2 · 1 location(s) · Navy General Hospital, Beijing · NCT06471946Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01515527Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a
Phase 1 · 1 location(s) · Laguna Biotherapeutics, Inc. · NCT07573111
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.